Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
30 sep 2009 - 07:52
Statutaire naam
Crucell N.V.
Titel
Crucell Strengthens its Vaccine Sales in the UK with a Dedicated Marketing and Sales Organization
Bericht
Leiden, The Netherlands (September 30, 2009) – Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced the launch of its own dedicated marketing and sales organization in the United Kingdom by acquiring an experienced team, to further strengthen its vaccine sales position in one of the largest vaccine markets in Europe.
Crucell’s UK team will market and sell Crucell’s travel vaccines Epaxal® (aluminum-free hepatitis A vaccine), Vivotif® (oral typhoid fever vaccine) and Dukoral® (oral vaccine against cholera and travelers’ diarrhea), as well as its registered virosomal adjuvanted influenza vaccine Inflexal® V. Distribution of the travel vaccines will start immediately and distribution of the influenza vaccines will start in 2010. Crucell has identified the UK as a high-potential market that deserves extra attention.
“In markets where Crucell has established its own dedicated marketing and sales organization, we have been able to increase our market share substantially and cost efficiently. Building a dedicated organization fully focused on selling our travel and respiratory vaccines in the UK will enable us to penetrate this market much more effectively and is therefore a logical step in expanding our current reach” said Ronald Brus, Crucell’s Chief Executive Officer.
Datum laatste update: 09 januari 2026